EI
The startup develops regenerative medicines that target the molecular mechanisms of aging by identifying blood factors that regulate biological repair and regeneration. Their approach aims to prevent and treat age-related diseases by reversing the damage caused by aging at a cellular level.
Updated 18 months ago
Funding
$60.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PMFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops regenerative medicines that target the molecular mechanisms of aging by identifying blood factors that regulate biological repair and regeneration. Their approach aims to prevent and treat age-related diseases by reversing the damage caused by aging at a cellular level.